1-18 of 18
Keywords: Antithrombin
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (1996) 26 (2): 85–89.
Published Online: 28 April 2009
...J.W.M. Krulder; A.F. Strebus; A.E. Meinders; E. Briët The aim of the study was to determine the effect of the antithrombin concentration on the anticoagulant response to heparin in vitro. Pooled plasma was depleted of antithrombin using heparin Sepharose. Unfractionated heparin (final concentration...
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (1996) 26 (Suppl. 1): 92–95.
Published Online: 28 April 2009
... tissue factor and IL-6 release by mononuclear cells (MNC), but enhanced IL-1β-evoked tissue factor activity. Clinical antithrombin (AT) concentrates inhibited, in a dose-dependent manner, tissue factor and IL-6 production by MNC and human umbilical vein endothelial cells (HUVEC). The three...
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (1991) 21 (4): 208–218.
Published Online: 24 April 2009
... of factor Xa. Factor IX Factor VIII Factor X Antithrombin Feedback control Mathematical models Haemostasis 1991;21:208-218 © 1991 S. Karger AG, Basel 0301-0147/91 /0214-0208S2.75/0 Interaction of Feedback Control and Product Inhibition in the Activation of Factor X by Factors IXa and VIII Jolyon...
Journal Articles
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (1990) 20 (Suppl. 1): 146–153.
Published Online: 24 April 2009
..., for heparan sulfate. One such structure is the antithrombin-binding region which is comprised by a specific pentasaccharide sequence with a 3-O-sulfated GlcN marker group. Aspects of regulation of polymer modification are discussed. 24 4 2009 © 1990 S. Karger AG, Basel 1990 Copyright / Drug...
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (1990) 20 (Suppl. 1): 180–192.
Published Online: 24 April 2009
... heparin Anti-factor Xa Antithrombin Haemostasis 1990;20(suppl 1): 180-192 © 1990 S. Karger AG. Basel 0 3 0 1 - 0 14 7 /9 0 /0 2 0 7 -0 180S2.75/0 In vitro and ex vivo Activities of CY216: Comparison with Other Low Molecular Weight Heparins F.A. Ofosu Canadian Red Cross Society, Blood Transfusion...
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (1990) 20 (Suppl. 1): 129–131.
Published Online: 24 April 2009
... bound in rabbits for at least 24 h and is able to enhance the inactivation process of thrombin and factor Xa. Heparin subcutaneously (200 U/kg) injected for 2 weeks resulted in an enhanced inactivation of thrombin and factor Xa by the endothelium. The antithrombin-enhancing activity persists longer than...
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (1990) 20 (Suppl. 1): 14–29.
Published Online: 24 April 2009
... as well as a number of protective functions. The activities of thrombin and other serine proteases are modulated by the serine potease inhibitors (serpins), including antithrombin III and heparin cofactor II which are important in regulating the physiological anticoagulant action of glycosaminoglycans...
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (1989) 19 (3): 152–159.
Published Online: 24 April 2009
...S. Schulman; H. Johnsson; B. Wiman In order to assess thrombogenicity and liver toxicity of different coagulation factor concentrates, antithrombin III, soluble fibrin, alanine aminotransferase (ALAT) and gamma-glutamyl transpeptidase (GT) were measured in samples taken before, 30 min and 24 h...
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (1990) 20 (5): 253–262.
Published Online: 24 April 2009
...Anne Karin Lindahl; Per Morten Sandset; Ulrich Abildgaard The mean levels of fibrinopeptide A (FPA), thrombin-antithrombin complex (TAT), and soluble fibrin (tPA method) in cancer patients (n = 32) were intermediate between those of patients with cerebral infarction and pancreatitis who had...
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (1988) 18 (Suppl. 3): 48–54.
Published Online: 23 April 2009
... to show that the effect of heparin on platelets is antibody- and antithrombin-III-independent. LMW heparin fractions in general exhibit a reduced platelet activating activity although there are differences between the LMW heparin fractions available. The stimulating effect of LMW heparin on platelets...
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (1986) 16 (Suppl. 2): 1–7.
Published Online: 22 April 2009
... Heparin, low molecular weight Heparin fragment Heparin fraction Antifactor Xa Antithrombotic Anticoagulant Antithrombin Haemostasis 16: suppl. 2, pp. 1-7 (1986) ©1986 S. Karger AG, Basel 0301-0147/86/0168-0001$2.75/0 Heparin and Its Low Molecular Weight Derivatives: Anticoagulant...
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (1977) 6 (2): 98–109.
Published Online: 16 April 2009
...-Phe-Val-Arg- p -nitroanilide (S 2160). After thrombin addition to plasma, only about 1.7 % of the added thrombin activity was recovered in the α 2 -macroglobulin precipitate. It is suggested that the contribution of α 2 -macroglobulin to the antithrombin activity of normal plasma is of little...
Journal Articles
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (2000) 30 (Suppl. 2): 48–56.
Published Online: 17 November 2004
... approximately one-third to the anticoagulant effect of heparin, the remaining being accounted for by antithrombin. Released TFPI, but not plasma TFPI, contains the basic carboxy-terminal tail which is important for the anticoagulant effect. UFH and LMWH exert differential effects on intravascular TFPI. UFH...
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (2003) 33 (3): 144–156.
Published Online: 02 June 2004
...Tomas Velan; Wayne L. Chandler The in vivo concentration of active thrombin and the second-order rate constant for the inhibition of thrombin by antithrombin (k inh ) were estimated in patients undergoing cardiopulmonary bypass (CPB) based on measured levels of hemostatic markers in combination...
Journal Articles
Pathophysiology of Haemostasis and Thrombosis (2002) 32 (Suppl. 3): 56–65.
Published Online: 20 June 2003
...Jawed Fareed; Debra Hoppensteadt; Omer Iqbal; Mehmut Tobu; Bruce E. Lewis Argatroban was the very first antithrombin agent that was approved for clinical use. It represents a synthetic arginomimetic drug with multiple pharmacologic properties. Unlike other antithrombin drugs, argatroban...
Journal Articles